Jyong Biotech's 'Cellular Communication Platform' Shines, Clinching Innovation Gold at 2025 Taipei Biotech Awards

Taipei, Taiwan – September 29, 2025 – In a momentous event that underscores the relentless pursuit of scientific excellence, Jyong Biotech, a pioneering force in biotechnological innovation, has proudly announced its victory of the prestigious Innovation Gold Award in the Pharmaceutical Category at the 2025 Taipei Biotech Awards.

This esteemed recognition celebrates the company's groundbreaking 'Cellular Communication Platform,' a revolutionary technology poised to transform the landscape of medicine.

The annual Taipei Biotech Awards, a beacon for innovation in the life sciences, brings together the brightest minds and most impactful technologies, drawing sponsorship from the Taipei City Government, the Ministry of Economic Affairs, and other key governmental bodies.

Jyong Biotech's triumph stands as a testament to its unwavering commitment to addressing some of humanity's most pressing health challenges.

At the heart of this award-winning innovation is Jyong Biotech's advanced 'Cellular Communication Platform.' This sophisticated technology leverages the intricate language cells use to communicate, specifically focusing on extracellular vesicles (EVs) derived from potent stem cells.

These naturally occurring nano-carriers are engineered to deliver a precise payload of therapeutic factors, effectively restoring cellular function and significantly enhancing the body’s innate healing capabilities.

The platform's potential applications are vast and deeply impactful. Researchers and medical professionals are particularly excited about its promise in combating age-related degenerative diseases, offering new hope for extending healthy lifespans and improving the quality of life for an aging global population.

Furthermore, the technology holds immense promise for developing novel treatments for a wide spectrum of autoimmune diseases, conditions that currently affect millions worldwide with limited effective therapies.

Dr. Jyong-Wan Luo, the visionary CEO of Jyong Biotech, expressed profound gratitude and pride during the acceptance speech.

“Winning the Innovation Gold Award is a tremendous honor and a powerful validation of our team’s dedication and pioneering spirit,” Dr. Luo stated. “Our 'Cellular Communication Platform' represents a significant leap forward in understanding and harnessing cellular interactions for therapeutic benefit.

We believe this technology will unlock unprecedented opportunities to combat complex diseases and profoundly improve human health globally.”

This accolade not only highlights Jyong Biotech’s scientific prowess but also reinforces Taiwan’s growing reputation as a global hub for biotechnology and medical innovation.

The company's achievement is a clear indicator of the robust research and development ecosystem fostered within the region.

Looking ahead, Jyong Biotech remains steadfast in its mission to translate cutting-edge scientific discoveries into practical, life-changing treatments. The success of the 'Cellular Communication Platform' at the 2025 Taipei Biotech Awards marks a pivotal moment, signaling a new era of therapeutic possibilities and solidifying Jyong Biotech’s position at the forefront of biotechnological advancement.